At the ESMO Congress 2024, Karine Tawagi, MD, of University of Illinois, and Christopher Wallis, MD, PhD, of University of Toronto, provide an overview of some of the most relevant research updates from the meeting in renal cell carcinoma. Among the highlights are the SUNNIFORECAST and TiNivo-2 trials. ...
nccRCC
Advertisement
The combination of ipilimumab/nivolumab may be a new standard in some subgroups of patients with metastatic nccRCC.
Drs. Barata and Tawagi provide updates in nccRCC, including SAMETA, PAPMET2, SUNNIFORECAST, and updated NCCN guidelines.
In anticipation of ESMO, Dr. Katy Beckermann previews various clinical trials and studies to be presented in kidney cancer.
Patients either underwent 54 weeks of treatment with everolimus 10 mg per day or treatment with a matching placebo.
The panel concludes with an overview of advancements and upcoming trials in the treatment of nccRCC.
The panel weighs the progress and challenges of adjuvant pembro and addresses the toxicity profiles of IO/TKI regimens.
The panel delves into the challenges and treatment approaches for various rare subtypes of nccRCC, including translocation.
CEUS for the assessment of nccRCC can provide a more sensitive alternative to conventional ultrasound imaging.
The panel highlights recent advancements in combination therapies for nccRCC, with a focus on KEYNOTE-B61 and cabo-nivo.
The panel focuses on CN, oligometastatic disease treatment, and advancements in systemic therapies over the past few decades.
Advertisement
Conference Coverage
The first part of five segments from the live podcast, roundtable session on radioligands.
During the final part of this panel, novel ADCs are explored and analyzed for use in different settings.
During the fourth segment of this panel, novel ADCs including HER3, Nectin-4, and BT8009 are analyzed.
In the third part of this panel, the use of HER2 ADCs in bladder cancer is explored.
In the second segment of this panel, the use of sacituzumab govitecan monotherapy and combinations is discussed.
In the first part of this panel, the use and impact of enfortumab vedotin in the bladder cancer landscape is considered.
Advertisement
Advertisement
Latest News
The first part of five segments from the live podcast, roundtable session on radioligands.
Part three of this prostate cancer roundtable covers prognostic factors such as Gleason scores and genomic assays.
Part two of this roundtable features a discussion on the role of bone scans compared to the newer PSMA PET scans.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.